COMMANDER HF 2018.

Study characteristics
Methods	Randomised, controlled, double‐blind trial
Participants	Heart failure, sinus rhythm, coronary artery disease; N = 5022
Interventions	Rivaroxaban versus placebo
Outcomes	The primary efficacy outcome was the composite of death from any cause, myocardial infarction, or stroke. Secondary efficacy outcomes included death from cardiovascular causes, re‐hospitalisation for decompensation of HF, rehospitalization for cardiovascular events, and the composite of death from cardiovascular causes or re‐hospitalisation for decompensation of HF.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Participants were randomised using an interactive web response system and permuted blocks of four.
Allocation concealment (selection bias)	Low risk	Participants were randomised using an interactive web response system and permuted blocks of four.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blind study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Outcomes were confirmed by investigators using an extensive, dedicated case‐report form, with source‐data verification by the sponsor’s clinical operations team.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	In total, 244 participants did not complete the study, were lost to follow‐up, withdrew consent, or had other reasons.
Selective reporting (reporting bias)	Low risk	The results of the study showed that treatment had no effect on outcome, thus this was therefore a negative study.